Insulin Lispro
| 證據等級: L5 | 預測適應症: 9 個 |
目錄
Insulin Lispro: From Diabetes Mellitus to Autoimmune Oophoritis
One-Sentence Summary
Insulin lispro is a rapid-acting insulin analog used to treat diabetes mellitus. The TxGNN model predicts it may be relevant to autoimmune oophoritis, but this ranking is based on model score alone — no clinical trials and no literature currently support this specific pairing.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Diabetes mellitus (well-established use for insulin lispro; not sourced from this evidence pack, as no Taiwan license record exists) |
| Predicted New Indication | Autoimmune oophoritis |
| TxGNN Prediction Score | 99.78% |
| Evidence Level | L5 |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for insulin lispro in this evidence pack (flagged as a High-severity data gap). Based on general pharmacological knowledge, insulin lispro acts as an insulin receptor agonist, promoting glucose uptake and regulating metabolism — a mechanism with no established direct link to ovarian autoimmune processes.
The relationship between diabetes mellitus and autoimmune oophoritis appears to be one of comorbidity, not shared treatment mechanism: autoimmune oophoritis can co-occur with other autoimmune endocrine diseases, including type 1 diabetes, as part of polyglandular autoimmune syndromes. This means patients with autoimmune oophoritis may separately require insulin for a co-existing diabetes diagnosis — it does not imply insulin lispro treats the oophoritis itself.
Because the TxGNN score reflects a knowledge-graph association rather than a validated causal or therapeutic pathway, and because no clinical trials or literature exist for this specific drug-disease pair, this candidate should be interpreted as a hypothesis-generating signal only, not a therapeutic lead.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence level is L5 (model prediction only) with no clinical trials or literature support, and the proposed mechanistic link is an indirect disease comorbidity rather than a plausible treatment pathway. Combined with missing TFDA label/safety data (a blocking gap), this candidate cannot proceed to safety review.
To proceed, the following is needed:
- TFDA label warnings/contraindications (DG001, blocking — required before any S1 safety screening)
- Insulin lispro mechanism of action data from DrugBank (DG002)
- A mechanistic or preclinical study directly linking insulin signaling to ovarian autoimmune pathology, rather than relying on diabetes comorbidity as a proxy
- Note: of the 9 candidates evaluated for this drug, only “pancreatic agenesis” (rank 7) returned literature, and that literature was a general diabetes-insulin review rather than disease-specific evidence; three lipodystrophy-related candidates were flagged as likely reflecting insulin’s known adverse association with lipoatrophy rather than a therapeutic signal, and should not be pursued as indications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.